Article

Glaucoma biomarkers under study

The relationship between IOP and scleral response could serve as a biomarker for glaucoma and represents one direction glaucoma research is taking.

Biomarker studies investigating this complex relationship could be particularly important because half or more of the people with open-angle glaucoma never have an eye pressure above normal, said Harry A. Quigley, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.

"We should no longer be surprised that open-angle glaucoma happens to people with normal pressure," said Dr. Quigley, the A. Edward Maumenee Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore.

Future directions

The ability to measure scleral stiffness would be helpful, although currently there is no method of doing this in living eyes.

Researchers at several centers are developing methods to measure scleral stiffness indirectly, and as technology improves it may be possible within a few years to measure the stiffness of the sclera and changes in the behavior of the lamina cribrosa directly in response to changes in eye pressure, Dr. Quigley said. This accomplishment might make it possible to use IOP change as a biomarker.

Another avenue of research would be to determine whether the mean level of IOP or the degree of fluctuation is the more important biomarker indicator.

"Our ability to measure the IOP on a continuous basis represents a very important second future direction," Dr. Quigley said. "It's only when we have continuous readout of eye pressures that we're finally going to understand much more about the risk of IOP."

He also said that ophthalmologists are familiar with the concept of eye pressure pushing out on the optic nerve, a force opposed slightly by the cerebrospinal fluid pressure. However, engineering studies suggest that the behavior of the sclera is equally or even more important since the scleral in-plane stress that generates strain pulling outward on the lamina cribrosa may be a greater force. And this force may be potentially much more important in many humans in translating IOP stress to the axons.

In the eyes of human specimens that have changed due to glaucoma, the lamina cribrosa is pulled outward and compressed downward, he added. It is the outward stress behind Bruch's membrane that potentially generates damage to astrocytes, axons, and capillaries in the nerve head.

Dr. Quigley also commented on the recent discovery that there are at least two components to damage in the optic nerve head. The prelaminar loss of axons, where there is no connective tissue in the primate or human nerve head, is one component, and the deformation of the laminar cribrosa is the second. IOP is associated with both of those, but topography measurements assess both together, suggesting that the topography measurement is not a direct measure of ganglion cell loss but rather a measurement of both of those components.

According to Dr. Quigley, the pressure-related component of glaucoma would relate to the change in the sclera, but once the axons are injured, many other variables must be taken into account. And how well the ganglion cells tolerate the injury would not necessarily be related to an individual's IOP.

"The IOP component of glaucoma is not going to explain everything," Dr. Quigley said. "Nothing explains everything."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.